Impact of Idarucizumab and Andexanet Alfa on DOAC Plasma Concentration and ClotPro<sup>®</sup> Clotting Time: An Ex Vivo Spiking Study in A Cohort of Trauma Patients

Impact of Idarucizumab and Andexanet Alfa on DOAC Plasma Concentration and ClotPro<sup>®</sup> Clotting Time: An Ex Vivo Spiking Study in A Cohort of Trauma Patients

Specific antagonists have been developed for the reversal of direct oral anticoagulants (DOAC). We investigated the impact of these reversal agents on the plasma concentration and visco-elastic test results of dabigatran and factor Xa inhibitors. After baseline measurements of dabigatran, the plasma...

Full description

Bibliographic Details
Main Authors: Daniel Oberladstätter, Christoph J. Schlimp, Johannes Zipperle, Marcin F. Osuchowski, Wolfgang Voelckel, Oliver Grottke, Herbert Schöchl
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Journal of Clinical Medicine
Subjects:
DOAC
reversal
Idarucizumab
Andexanet alfa
RVV-test
ECA-test
Online Access:https://www.mdpi.com/2077-0383/10/16/3476

Similar Items

Similar Items